The treatment of hepatitis C virus (HCV) infection has been revolutionized in recent years by the development of direct-acting antiviral regimens that do not contain peginterferon (pegIFN) and/or ribavirin (RBV).
INTRODUCTION
The development of direct-acting antiviral agents (DAAs) represents a major evolution in the treatment of hepatitis C virus (HCV) infection in both efficacy and safety compared with peginterferon (pegIFN) in combination with ribavirin (RBV) [1] .
While the more recently developed DAAs have a lower potential for drug-drug interactions (DDIs) relative to the first-generation HCV NS3 protease inhibitors, the majority of new DAAs have some interaction with cytochrome P450 (CYP) enzymes, e.g., CYP3A4, and/or transporters such as P-glycoprotein (P-gp) [2] . In addition, [3] .
DCV-the benchmark pangenotypic NS5A inhibitor approved in the US, Europe, Japan, and multiple nations across Latin America, the Middle East, and Asia Pacific-has been shown to be highly effective and generally well tolerated in phase 3 studies with other HCV DAAs, including sofosbuvir (SOF), asunaprevir (ASV), and ASV with beclabuvir (BCV) [4] [5] [6] [7] [8] [9] [10] .
Furthermore, DCV has been shown to have a low potential for DDIs. Simple [14] .
Mechanistic Assessments of DCV DDIs (Object)
Reduced DCV Exposure via Induction of CYP3A4 Strong induction of CYP3A4 by steady-state rifampin resulted in significantly reduced DCV exposure (C max , 56% reduction; AUC, 79% reduction) to a degree likely to attenuate antiviral efficacy (Study AI444-012; data on file) and led to the contraindication of DCV co-administration with strong inducers of CYP3A4. Lesser reductions in DCV exposure during co-administration with moderate inducers, e.g., the antiretroviral efavirenz (described below), can be effectively and safely managed with dose modification (DCV 90 mg once daily [QD]).
Increased DCV Exposure via Inhibition of CYP3A4/P-gp
Co-administration of DCV with steady-state ketoconazole-a strong inhibitor of CYP3A4 and P-gp-resulted in a three-fold increase in DCV exposure (AUC; Study AI444-005; data on file). Results from this study support the dose modification of DCV to 30 mg QD during co-administration with strong inhibitors of CYP3A4. In a another DDI study with single-dose cyclosporine (Study AI444-065)-a strong P-gp inhibitor but weak CYP3A4 inhibitor-DCV AUC increased by only 40% during co-administration relative to administration alone, and suggests that co-administration of DCV with P-gp inhibitors without meaningful inhibitory effects on CYP3A4 is unlikely to have clinically relevant effects on DCV exposure [12] . Based on these data, no dose adjustment of DCV is recommended for co-administration with cyclosporine. 
Inhibition of P-gp by DCV
The co-administration of DCV with digoxin, both agents at steady-state, resulted in a 27% increase in digoxin AUC during co-administration, relative to administration alone (Study AI444-027; data on file). Similar increases in digoxin exposure were also noted when it was co-administered with DCV and ASV (also a P-gp inhibitor; Study AI447-040), suggesting that there is no additive risk of a DDI during co-administration of P-gp substrates with DCV when combined with ASV [15] . The observations from Studies AI444-027 (data on file) and AI447-040 suggest that caution should be used when DCV is co-administered with P-gp substrates with a narrow therapeutic index.
Inhibition of OATP1B1/B3 and/or BCRP by DCV
During co-administration with DCV at steady-state, single-dose rosuvastatin exposure was increased (C max , two-fold; AUC, 58% increase; Study AI444-054) by weak to moderate inhibition of OATP1B1/B3 and/or BCRP [14] . Based upon data during co-administration of DCV with ASV (a sensitive OATP substrate whose exposure is not meaningfully affected by DCV) [16] , it is likely that the effect of DCV (a BCRP inhibitor) on the exposure of rosuvastatin (both an OATP and a BCRP substrate), is mediated primarily through BCRP. Caution is recommended during the co-administration of DCV and substrates of OATP1B1/B3 and/or BCRP with a narrow therapeutic index.
DCV DDIS AND DOSING GUIDANCE WITH OTHER ANTIVIRAL AGENTS
The DDI profile of DCV has been assessed with other HCV regimen partners and antiretroviral agents. GMRs of C max and AUC and associated 90% confidence intervals (CIs) from individual DDI studies are presented in Table 1 .
HCV DAA Regimen Partners
There are no clinically significant DDIs between DCV and ASV (Studies AI447-009 and AI447-011) [16, 17] , ASV and BCV in combination (Study AI443-014) [18] , or SOF (Study AI444-040) [19] , and dose modifications during co-administration are not required. No dose adjustments are required during the co-administration of DCV with simeprevir (Study HCP1005) [20] . Steady-state co-administration with the strong CYP3A4 inhibitor, telaprevir, resulted in a 2.3-fold increase in DCV exposure (AUC) in Study AI444-067 (data on file); the interaction with boceprevir, also a strong inhibitor of CYP3A4, is predicted to be similar.
Antiretroviral Agents
The estimated global prevalence of HCV co-infection with human immunodeficiency virus (HIV) varies widely by geography and demography; among intravenous drug users, the co-infection rate may approach 100% [21] .
The complex nature of many HIV regimens in terms of their DDI profile and the preference not to switch well-tolerated regimens in virally suppressed patients implies that the ideal HCV partner regimen for the treatment of co-infection has a low probability of DDIs. The probability of a DDI between DCV and antiretroviral agents often reflects the degree of impact the antiretroviral regimen has on CYP3A4 [22] . DCV in combination with SOF has been shown to be effective and generally well tolerated in phase 3 evaluations in an HIV/ HCV genotype 1-4 co-infected patient population receiving all major HIV treatment regimens [7] . 
Protease Inhibitors

Integrase Inhibitors
The lack of clinically meaningful steady-state DDIs between DCV and unboosted integrase inhibitors has been demonstrated with raltegravir in HCV-HIV co-infected patients (ANRS HC30 QUADRIH study) [25] and with dolutegravir in healthy subjects (Study NCT02082808) [26] . In both studies, no clinically meaningful changes to the exposure of the integrase inhibitor were observed (raltegravir exposure was reduced by 6% and dolutegravir exposure increased by 33%), and DCV exposures were either comparable with historic controls (ANRS HC30 QUADRIH study) [25] or unaffected (Study NCT02082808) [26] . GMRs of C max and AUC and associated 90% CIs from individual DDI studies are presented in Table 2 .
Immunosuppressants
As HCV is a chronic disease of the liver that ultimately results in hepatic failure, it is likely that DCV will be co-administered with immunosuppressants in patients who have received organ transplantation.
As described above, steady-state DCV exposure was not affected to a meaningful degree when administered to healthy subjects in combination with single doses of cyclosporine (DCV AUC increased by 40% during co-administration) or tacrolimus (DCV AUC increased by 5% during co-administration) sufficient to mimic steady-state concentrations (Study AI444-065); cyclosporine and tacrolimus exposures were unaffected (B5% changes in C max and AUC during co-administration) [12] .
No meaningful DDIs are predicted with sirolimus (primarily metabolized by CYP3A4
and also a substrate of P-gp) and mycophenolate mofetil (metabolized by both
UDP-glucuronosyltransferases [UGTs] and CYP3A4).
The lack of requirement for DCV dose adjustments during co-administration with immunosuppressants is also further supported by the observation that DCV (in combination with SOF ± RBV) is highly effective and generally well tolerated in a phase 3 evaluation in post-transplant recipients with recurrent HCV infection (N = 53); furthermore, only one patient required minor dosage adjustment of immunosuppressive medications (tacrolimus dose reduced from 3.5 to 3.0 mg), and there were no events of graft rejection [6] .
Narcotic Analgesics
Approximately, 70% of the global population of intravenous drug users are infected with HCV [27] . The effect of steady-state DCV on the exposure of oral opioids (methadone and buprenorphine/naloxone) administered at stable doses was assessed in non-HCV-infected, opioid-dependent adults in Study AI444-064 [28] . During co-administration, the exposures (AUCs) of DCV and R-methadone (active methadone enantiomer) were unaffected, and clinically insignificant increases in the exposures of buprenorphine (31%) and norbuprenorphine (62%) were observed; the 90% GMRs of opioid AUCs were contained entirely within the literature-derived ranges of no effect (R-methadone, 0.7-1.23; buprenorphine and norbuprenorphine, 0.5-2.0) and no dose adjustments during co-administration were required. Pharmacodynamic measures of opioid activity were also unaffected [28] .
Sedatives
The lack of a clinically relevant interaction between DCV and the benzodiazepine, midazolam, has been described previously (Study AI444-008) [13] , and co-administration does not require dose modification. Similarly, 
Cardiovascular Agents
The majority of patients infected with HCV were born between the years of 1945-1965 and, therefore, given the mean age of the HCV population, the concomitant administration of DCV with cardiovascular agents is likely [33] . There are no predicted DDIs or cautionary requirements when DCV is co-administered with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or phosphodiesterase-5 inhibitors.
Antiarrhythmics
The requirement for caution during co-administration of DCV with digoxin due to DCV-based inhibition of P-gp resulting in increased digoxin exposure (AUC, 27% increase) has been described above (Study AI444027; data on file).
Cases of severe bradycardia and heart block
have been observed when DCV is co-administered with SOF and concomitant amiodarone (CYP3A4 substrate/inhibitor, P-gp inhibitor) with or without other drugs that lower heart rate; similar observations have also been made with other SOF-based regimens [34] . Cases are potentially life threatening; therefore, amiodarone should only be used in patients on DCV and SOF when other alternative antiarrhythmic treatments are not tolerated or are contraindicated. Close monitoring is required when the concomitant use of amiodarone is considered to be unavoidable; patients who are identified as being at high risk of bradyarrhythmia should be continuously monitored for 48 h in an appropriate clinical setting. Furthermore, due to the long half-life of amiodarone, appropriate monitoring should also be carried out for patients who have discontinued amiodarone within the past few months and are to be initiated on DCV in combination with SOF [11]. The exact mechanism of this toxicity is not established and a direct study has not been conducted.
Calcium Channel Blockers
The interaction between DCV and calcium channel blockers has not been studied directly, and the recommendation for caution during co-administration due to predicted increases in DCV exposure is based upon inhibition of CYP3A4 (diltiazem, nifedipine, and amlodipine) or CYP3A4 and P-gp (verapamil).
Anticoagulants
There is no predicted DDI between DCV and warfarin (metabolized primarily by CYP3A4 [R-isomer] and CYP2C9 [S-isomer]); however, the exposure of dabigatran etexilate is predicted to be increased by P-gp inhibition by DCV during co-administration; thus, safety monitoring due to the narrow therapeutic index of dabigatran is recommended.
HMG-CoA Reductase Inhibitors
The recommendation of caution during co-administration of DCV with HMG-CoA reductase inhibitors, in general, is based on the observed increase in rosuvastatin exposure in Study AI444-054 (OATP/BCRP inhibition by DCV) as described above [14] , and similar effects with the OATP and/or BCRP substrates, atorvastatin, fluvastatin, simvastatin, pitavastatin, and pravastatin are predicted.
Systemic Corticosteroids
Systemic dexamethasone is a strong inducer of CYP3A4 and therefore co-administration with DCV is contraindicated.
Anticonvulsants
Concomitant administration of anticonvulsants that are strong inducers of CYP3A4 (e.g., carbamazepine, oxcarbazepine, phenobarbital, and phenytoin) is contraindicated for co-administration with DCV. John's wort (Hypericum perforatum; a strong inducer of CYP3A4 and thus contraindicated for concomitant use with DCV) [36] and taurine (commonly found in body-building supplements and energy drinks) [38] .
It is suggested that prior to the initiation of DCV-based therapy, health-care professionals discuss with the patient the use of herbal preparations and the consumption of food and drink known to impact CYP3A4 activity.
REAL-WORLD EXPERIENCES
Real-world DDI frequency data for DCV are limited; however, DDI frequencies with NS5A-containing regimens were discussed in the report of a German outpatient clinic cohort study in HCV mono-infected patients (N = 261) [39] 
CONCLUSIONS
The DDI studies conducted during the development program of DCV demonstrate that it has few or no clinically relevant DDIs with HCV DAA regimen partners [16] [17] [18] [19] [20] , first-line antiretrovirals [23] [24] [25] [26] , immunosuppressants [12] , narcotic analgesics [28] , gastric acid-reducing agents [35] , or other common concomitant medications (e.g., hormonal contraceptives [32] , antidepressants [SSRIs; data on file], and benzodiazepine sedatives) [13] . Furthermore, real-world data, although limited, suggest that the regimen of DCV/SOF has a favorable DDI profile, compared with other NS5A inhibitor-based regimens [39] .
When unavoidable DDIs are present, the predictability of CYP3A4-based DDIs combined with the flexibility to dose adjust when co-administering DCV with strong CYP3A4 inhibitors (DCV 30 mg QD) or moderate CYP3A4 inducers (DCV 90 mg QD) helps clinicians to effectively manage these DDIs.
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